Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis

References

• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J clin oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Suzuki R. NK/T cell lymphoma: updates in therapy. Current Hematologic Malignancy Reports. 2018;13(1):7–12. doi:10.1007/s11899-018-0430-5
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186–2194. doi:10.1038/sj.leu.2403955
   PubMed Web of Science ®Google Scholar
• Haverkos BM, Pan Z, Gru AA, et al. Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Current Hematologic Malignancy Reports. 2016;11(6):514–527. doi:10.1007/s11899-016-0355-9
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528–2540. doi:10.1182/blood-2017-12-791418
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351–2356. doi:10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leukemia Lymphoma. 2007;48(2):396–402. doi:10.1080/10428190601059795
   PubMed Web of Science ®Google Scholar
• Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy–result of chemotherapy in NK/T-cell lymphoma. Acta oncologica. 2003;42(7):779–783.
   PubMed Web of Science ®Google Scholar
• Guo HQ, Liu L, Wang XF, et al. Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. Molecular Clinical Oncology. 2014;2(6):1172–1176. doi:10.3892/mco.2014.368
   PubMedGoogle Scholar
• Wang JH, Wang H, Wang YJ, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Oncotarget. 2016;7(23):35412–35422. doi:10.18632/oncotarget.8643
   PubMedGoogle Scholar
• Jing XM, Zhang ZH, Wu P, et al. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma. Leuk Res. 2016;47:26–31. doi:10.1016/j.leukres.2016.05.004
   PubMed Web of Science ®Google Scholar
• Li JW, Li YJ, Zhong MZ, Liu XL, Li J. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study. Eur J Haematol. 2018;100(3):247–256.
   Google Scholar
• Wang JH, Wang L, Liu CC, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget. 2016;7(20):29092–29101. doi:10.18632/oncotarget.8647
   PubMedGoogle Scholar
• Wang H, Wuxiao ZJ, Zhu J, et al. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leukemia Lymphoma. 2015;56(4):971–977.
   PubMed Web of Science ®Google Scholar
• Bi XW, Xia Y, Zhang WW, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94(9):1525–1533. doi:10.1007/s00277-015-2395-y
   PubMed Web of Science ®Google Scholar
• Yang L, Liu H, Xu XH, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Medical Oncol. 2013;30(4):720. doi:10.1007/s12032-013-0720-7
   PubMed Web of Science ®Google Scholar
• Qi S, Yahalom J, Hsu M, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leukemia Lymphoma. 2016;57(11):2575–2583. doi:10.1080/10428194.2016.1180689
   PubMed Web of Science ®Google Scholar
• Huang L, Yuan B, Wu H, et al. Comparative study of l-asparaginase-based lop regimen over chop regimen before radiotherapy for stage iie extranodal nasal type NK/T cell lymphoma: a study of 2 centers. Clin Lymphoma Myeloma Leuk. 2017;17(3):152–158. doi:10.1016/j.clml.2016.12.003
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen M, Song Y, et al. Study of l-asparaginase, vincristine, and dexamethasone combined with intensity-modulated radiation therapy in early-stage nasal NK/T-cell lymphoma. Am J Clin Oncology. 2019.
   Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–221. doi:10.1182/blood-2003-05-1401
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J clin oncol. 2006;24(4):612–618. doi:10.1200/JCO.2005.04.1384
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Takata K, Yoshino T, et al. Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Science. 2014;105(11):1435–1441. doi:10.1111/cas.12526
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncology. 2016;17(3):389–400. doi:10.1016/S1470-2045(15)00533-1
   PubMed Web of Science ®Google Scholar
• NCCN guidelines version 2. 2019 T-cell lymphomas. Availbale from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361–2364. doi:10.1182/blood-2016-03-657379
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J clin oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi:10.1016/S1053-4296(03)00031-6
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126(12):1424–1432; quiz 1517. doi:10.1182/blood-2015-04-639336
   Web of Science ®Google Scholar
• Chen B, Zhu SY, Shi M, et al. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Med. 2018;7(12):5952–5961.
   Google Scholar
• Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009;88(7):647–652. doi:10.1007/s00277-008-0669-3
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a Phase 2 study. Blood. 2011;117(6):1834–1839. doi:10.1182/blood-2010-09-307454
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182–190. doi:10.1016/S0360-3016(02)02916-4
   PubMed Web of Science ®Google Scholar
• Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001;61(3):261–269. doi:10.1016/S0167-8140(01)00428-5
   PubMed Web of Science ®Google Scholar
• Lee J, Kim CY, Park YJ, Lee NK. Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. Blood Res. 2013;48(4):274–281. doi:10.5045/br.2013.48.4.274
   PubMedGoogle Scholar
• Zang J, Li C, Luo SQ, et al. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy–a single institution experience. Ann Hematol. 2015;94(4):583–591. doi:10.1007/s00277-014-2244-4
   PubMed Web of Science ®Google Scholar
• Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clinical Oncology. 2008;20(8):619–625. doi:10.1016/j.clon.2008.05.011
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang J, Zhang W, et al. Extended course and increased dose of initial chemotherapy for extranodal nasal type natural killer/t (nk/t)-cell lymphoma in patients <60 years old: a single-center retrospective cohort study. Medical Science Monitor. 2016;22:4297–4311.
   PubMed Web of Science ®Google Scholar
• Ma X, Guo Y, Pang Z, et al. A randomized Phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract. Radiother Oncol. 2009;93(3):492–497. doi:10.1016/j.radonc.2009.08.045
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93(11):1895–1901. doi:10.1007/s00277-014-2137-6
   PubMed Web of Science ®Google Scholar
• Ke QH, Zhou SQ, Du W, et al. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma. Blood Cancer J. 2014;4:e267. doi:10.1038/bcj.2014.88
   PubMed Web of Science ®Google Scholar
• Oh D, Ahn YC, Kim SJ, Kim WS, Ko YH. Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer/t-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys. 2015;93(3):677–683. doi:10.1016/j.ijrobp.2015.07.2267
   PubMed Web of Science ®Google Scholar
• Michot JM, Mazeron R, Danu A, et al. Concurrent etoposide, steroid, high-dose ara-c and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. European j Cancer. 2015;51(16):2386–2395. doi:10.1016/j.ejca.2015.07.009
   PubMed Web of Science ®Google Scholar
• Yoon DH, Kim SJ, Jeong SH, et al. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016;7(51):85584–85591. doi:10.18632/oncotarget.11319
   PubMed Web of Science ®Google Scholar
• Dong LH, Zhang LJ, Wang WJ, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leukemia Lymphoma. 2016;57(7):1600–1606. doi:10.3109/10428194.2015.1108415
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang L, Xie L, et al. A phase II prospective study of the “Sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget. 2017;8(30):50155–50163.
   PubMedGoogle Scholar
• Qi F, Wang WH, He XH, et al. Phase 2 study of first-line intensity modulated radiation therapy followed by gemcitabine, dexamethasone, and cisplatin for high-risk, early stage extranodal nasal-type nk/t-cell lymphoma: the green study. Int J Radiat Oncol Biol Phys. 2018;102(1):61–70. doi:10.1016/j.ijrobp.2018.05.046
   PubMed Web of Science ®Google Scholar
• Qi F, Chen B, Wang J, et al. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era. Leukemia Lymphoma. 2019;60(11):2679–2688. doi:10.1080/10428194.2019.1599111
   PubMed Web of Science ®Google Scholar
• Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leukemia Lymphoma. 2006;47(7):1274–1282. doi:10.1080/10428190600562823
   PubMed Web of Science ®Google Scholar
• Lin N, Song Y, Zheng W, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol. 2013;6:44. doi:10.1186/1756-8722-6-44
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez R, Huerta-Guzman J, Nambo MJ. Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial. Medical Oncol. 2013;30(3):637. doi:10.1007/s12032-013-0637-1
   PubMed Web of Science ®Google Scholar
• Zheng W, Gao Y, Ke X, et al. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer. 2018;18(1):910. doi:10.1186/s12885-018-4782-y
   PubMed Web of Science ®Google Scholar